<DOC>
	<DOCNO>NCT01837576</DOCNO>
	<brief_summary>The purpose study evaluate antipsoriatic effect 5 different combination calcipotriol plus betamethasone dipropionate Daivobet® gel vehicle compare Daivobet® gel order explore/find safe effective combination two component .</brief_summary>
	<brief_title>An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations Calcipotriol Plus Betamethasone Dipropionate Daivobet® Gel Vehicle Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subject must provide write information . Age 18 year . Males , female subject . Subjects lesion psoriasis vulgaris locate arm and/or legs and/or trunk . Subjects , opinion investigator , stable psoriasis Subjects psoriasis lesion ( plaque ) assess Total Clinical Score 4 9 inclusive individual item ≥ 1 . Subjects willing able follow study procedure complete whole study . Subjects affiliate social security system . Female childbearing potential negative urine pregnancy test Female subject pregnant , childbearing potential wish become pregnant study , breast feeding . Systemic treatment biological therapy within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever longer ) experimental biological product prior randomisation study . Systemic treatment therapy biologicals , ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4 week period prior randomisation study . Subjects use one follow topical drug treatment psoriasis prior randomisation study : Potent potent ( WHO group IIIIV ) corticosteroid ( 4 week ) . Subjects use phototherapy prior randomisation study : PUVA ( 4 week ) UVB ( 2 week ) . Subjects use one follow topical drug treatment psoriasis within two week prior randomisation study : WHO group III corticosteroid ( except use fortreatment scalp and/or facial psoriasis ) , Topical retinoids , Vitamin D analogue , Topical immunomodulators ( e.g . macrolides ) , Anthracen derivative , Tar , Salicylic acid Subjects use emollient select plaque within one week randomisation study . Initiation , expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalarial drug , lithium ACE inhibitor ) within 2 week prior randomization study . Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . Subjects known/suspected disorder calcium metabolism associate hypercalcemia within last 10 year , base medical history and/or subject interview . History severe disease serious current condition , opinion Investigator , would put subject risk participating study would interfere significantly evaluation study result study course Subjects accept biopsy positive Hepatitis B , Hepatitis C HIV test Subjects receive treatment non market drug substance within 4 week period prior randomisation longer , class substancerequires longer washout defined Subjects current participation interventional clinical Subjects know suspected hypersensitivity component ( ) investigational product . Subjects concomitant medical dermatological disorder ( ) might preclude accurate evaluation psoriasis test area . Subjects foresee intensive solar exposure study expose within two week precede screen visit . Subjects accept biopsy contraindication skin biopsy procedure . Subjects impossible contact case emergency . In opinion investigator , subject unlikely comply Clinical Study Protocol . Subjects exclusion period National Biomedical Research Register French Ministry Health randomization . Subject guardianship , hospitalize public private institution , reason research subject deprive freedom . Subjects previously randomise trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Calcipotriol</keyword>
	<keyword>Betamethasone Dipropionate</keyword>
</DOC>